Overall View of Chemical and Biochemical Weapons
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Alcohols Combined 1405
ALCOHOLS COMBINED 1405 Formulas: Table 1 MW: Table 1 CAS: Table 2 RTECS: Table 2 METHOD: 1405, Issue 1 EVALUATION: PARTIAL Issue 1: 15 March 2003 OSHA : Table 2 PROPERTIES: Table 1 NIOSH: Table 2 ACGIH: Table 2 COMPOUNDS: (1) n-butyl alcohol (4) n-propyl alcohol (7) cyclohexanol (2) sec-butyl alcohol (5) allyl alcohol (8) isoamyl alcohol (3) isobutyl alcohol (6) diacetone alcohol (9) methyl isobutyl carbinol SYNONYMS: See Table 3. SAMPLING MEASUREMENT SAMPLER: SOLID SORBENT TUBE TECHNIQUE: GAS CHROMATOGRAPHY, FID (Coconut shell charcoal, 100 mg/50 mg) ANALYTE: Compounds above FLOW RATE: 0.01 to 0.2 L/min DESORPTION: 1 mL 5% 2-propanol in CS2 Compounds: (1-3 ) (4-9) VOL-MIN: 2 L 1 L INJECTION -MAX: 10 L 10 L VOLUME: 1 µL SHIPMENT: Routine TEMPERATURE -INJECTION: 220 °C SAMPLE -DETECTOR: 250 - 300 °C STABILITY: See Evaluation of Method. -COLUMN: 35 °C (7 minutes), to 60 °C at 5 °C/minute, hold 5 minutes, up to BLANKS: 2 to 10 field blanks per set 120 °C at 10 °C /minute, hold 3 minutes. CARRIER GAS: He, 4 mL/min ACCURACY COLUMN: Capillary, fused silica, 30 m x 0.32-mm RANGE STUDIED: Not studied [1, 2]. ID; 0.5 µm film polyethylene glycol, DB- wax or equivalent BIAS: Not determined CALIBRATION: Solutions of analyte in eluent (internal OVERALL standard optional) PRECISION (Ö ): Not determined rT RANGE: See EVALUATION OF METHOD. ACCURACY: Not determined ESTIMATED LOD: 1 µg each analyte per sample PRECISION: See EVALUATION OF METHOD. APPLICABILITY: This method may be used to determine two or more of the specified analytes simultaneously. -
Rapid and Simultaneous Detection of Ricin, Staphylococcal Enterotoxin B
Analyst PAPER View Article Online View Journal | View Issue Rapid and simultaneous detection of ricin, staphylococcal enterotoxin B and saxitoxin by Cite this: Analyst,2014,139, 5885 chemiluminescence-based microarray immunoassay† a a b b c c A. Szkola, E. M. Linares, S. Worbs, B. G. Dorner, R. Dietrich, E. Martlbauer,¨ R. Niessnera and M. Seidel*a Simultaneous detection of small and large molecules on microarray immunoassays is a challenge that limits some applications in multiplex analysis. This is the case for biosecurity, where fast, cheap and reliable simultaneous detection of proteotoxins and small toxins is needed. Two highly relevant proteotoxins, ricin (60 kDa) and bacterial toxin staphylococcal enterotoxin B (SEB, 30 kDa) and the small phycotoxin saxitoxin (STX, 0.3 kDa) are potential biological warfare agents and require an analytical tool for simultaneous detection. Proteotoxins are successfully detected by sandwich immunoassays, whereas Creative Commons Attribution-NonCommercial 3.0 Unported Licence. competitive immunoassays are more suitable for small toxins (<1 kDa). Based on this need, this work provides a novel and efficient solution based on anti-idiotypic antibodies for small molecules to combine both assay principles on one microarray. The biotoxin measurements are performed on a flow-through chemiluminescence microarray platform MCR3 in 18 minutes. The chemiluminescence signal was Received 18th February 2014 amplified by using a poly-horseradish peroxidase complex (polyHRP), resulting in low detection limits: Accepted 3rd September 2014 2.9 Æ 3.1 mgLÀ1 for ricin, 0.1 Æ 0.1 mgLÀ1 for SEB and 2.3 Æ 1.7 mgLÀ1 for STX. The developed multiplex DOI: 10.1039/c4an00345d system for the three biotoxins is completely novel, relevant in the context of biosecurity and establishes www.rsc.org/analyst the basis for research on anti-idiotypic antibodies for microarray immunoassays. -
Copyrighted Material
1 Historical Milieu 1.1 Organophosphorus Nerve Agents 2 1.2 Blister Agents 5 1.3 Sternutator Agents 11 1.4 Chemical Weapons Convention (CWC) 13 1.4.1 Schedule of Chemicals 14 1.4.2 Destruction of Chemical Weapons 14 References 16 COPYRIGHTED MATERIAL Analysis of Chemical Warfare Degradation Products, First Edition. Karolin K. Kroening, Renee N. Easter, Douglas D. Richardson, Stuart A. Willison and Joseph A. Caruso. © 2011 John Wiley & Sons, Ltd. Published 2011 by John Wiley & Sons, Ltd. 2 ANALYSIS OF CHEMICAL WARFARE DEGRADATION PRODUCTS 1.1 ORGANOPHOSPHORUS NERVE AGENTS Organophosphorus (OP) type compounds, that is, deriva- tives containing the P=O moiety, were first discovered in the 1800s when researchers were investigating useful applica- tions for insecticides/rodenticides. There are many derivatives of organophosphorus compounds, however, the OP deriva- tives that are typically known as ‘nerve agents’ were discov- ered accidentally in Germany in 1936 by a research team led by Dr. Gerhard Schrader at IG Farben [1–4]. Schrader had noticed the effects and lethality of these organophosphorus compounds towards insects and began developing a new class of insecticides. While working towards the goal of an improved insecticide, Schrader experimented with numerous phosphorus-containing compounds, leading to the discovery of the first nerve agent, Tabun (or GA) (Figure 1.1). The potency of these insecticides towards humans was not realized until there was yet another accident, which involved a Tabun spill. Schrader and coworkers began experiencing symptoms, such as miosis (constriction of the pupils of the eyes), dizziness and severe shortness of breath, with numerous effects lasting several weeks [1, 4, 5]. -
Biological Toxins Fact Sheet
Work with FACT SHEET Biological Toxins The University of Utah Institutional Biosafety Committee (IBC) reviews registrations for work with, possession of, use of, and transfer of acute biological toxins (mammalian LD50 <100 µg/kg body weight) or toxins that fall under the Federal Select Agent Guidelines, as well as the organisms, both natural and recombinant, which produce these toxins Toxins Requiring IBC Registration Laboratory Practices Guidelines for working with biological toxins can be found The following toxins require registration with the IBC. The list in Appendix I of the Biosafety in Microbiological and is not comprehensive. Any toxin with an LD50 greater than 100 µg/kg body weight, or on the select agent list requires Biomedical Laboratories registration. Principal investigators should confirm whether or (http://www.cdc.gov/biosafety/publications/bmbl5/i not the toxins they propose to work with require IBC ndex.htm). These are summarized below. registration by contacting the OEHS Biosafety Officer at [email protected] or 801-581-6590. Routine operations with dilute toxin solutions are Abrin conducted using Biosafety Level 2 (BSL2) practices and Aflatoxin these must be detailed in the IBC protocol and will be Bacillus anthracis edema factor verified during the inspection by OEHS staff prior to IBC Bacillus anthracis lethal toxin Botulinum neurotoxins approval. BSL2 Inspection checklists can be found here Brevetoxin (http://oehs.utah.edu/research-safety/biosafety/ Cholera toxin biosafety-laboratory-audits). All personnel working with Clostridium difficile toxin biological toxins or accessing a toxin laboratory must be Clostridium perfringens toxins Conotoxins trained in the theory and practice of the toxins to be used, Dendrotoxin (DTX) with special emphasis on the nature of the hazards Diacetoxyscirpenol (DAS) associated with laboratory operations and should be Diphtheria toxin familiar with the signs and symptoms of toxin exposure. -
Biological Toxins As the Potential Tools for Bioterrorism
International Journal of Molecular Sciences Review Biological Toxins as the Potential Tools for Bioterrorism Edyta Janik 1, Michal Ceremuga 2, Joanna Saluk-Bijak 1 and Michal Bijak 1,* 1 Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland; [email protected] (E.J.); [email protected] (J.S.-B.) 2 CBRN Reconnaissance and Decontamination Department, Military Institute of Chemistry and Radiometry, Antoniego Chrusciela “Montera” 105, 00-910 Warsaw, Poland; [email protected] * Correspondence: [email protected] or [email protected]; Tel.: +48-(0)426354336 Received: 3 February 2019; Accepted: 3 March 2019; Published: 8 March 2019 Abstract: Biological toxins are a heterogeneous group produced by living organisms. One dictionary defines them as “Chemicals produced by living organisms that have toxic properties for another organism”. Toxins are very attractive to terrorists for use in acts of bioterrorism. The first reason is that many biological toxins can be obtained very easily. Simple bacterial culturing systems and extraction equipment dedicated to plant toxins are cheap and easily available, and can even be constructed at home. Many toxins affect the nervous systems of mammals by interfering with the transmission of nerve impulses, which gives them their high potential in bioterrorist attacks. Others are responsible for blockage of main cellular metabolism, causing cellular death. Moreover, most toxins act very quickly and are lethal in low doses (LD50 < 25 mg/kg), which are very often lower than chemical warfare agents. For these reasons we decided to prepare this review paper which main aim is to present the high potential of biological toxins as factors of bioterrorism describing the general characteristics, mechanisms of action and treatment of most potent biological toxins. -
Evaluated Gas Phase Basicities and Proton Affinities of Molecules; Heats of Formation of Protonated Molecules
Evaluated Gas Phase Basicities and Proton Affinities of Molecules; Heats of Formation of Protonated Molecules Cite as: Journal of Physical and Chemical Reference Data 13, 695 (1984); https://doi.org/10.1063/1.555719 Published Online: 15 October 2009 Sharon G. Lias, Joel F. Liebman, and Rhoda D. Levin ARTICLES YOU MAY BE INTERESTED IN Evaluated Gas Phase Basicities and Proton Affinities of Molecules: An Update Journal of Physical and Chemical Reference Data 27, 413 (1998); https:// doi.org/10.1063/1.556018 Density-functional thermochemistry. III. The role of exact exchange The Journal of Chemical Physics 98, 5648 (1993); https://doi.org/10.1063/1.464913 A consistent and accurate ab initio parametrization of density functional dispersion correction (DFT-D) for the 94 elements H-Pu The Journal of Chemical Physics 132, 154104 (2010); https://doi.org/10.1063/1.3382344 Journal of Physical and Chemical Reference Data 13, 695 (1984); https://doi.org/10.1063/1.555719 13, 695 © 1984 American Institute of Physics for the National Institute of Standards and Technology. Evaluated Gas Phase Basicities and Proton Affinities of Molecules; Heats of Formation of Protonated Molecules Sharon G. Lias Center for Chemical Physics, National Bureau of Standards, Gaithersburg, MD 20899 Joel F. Liebman Department of Chemistry, University of Maryland Baltimore County, Catonsville, MD 21228 and Rhoda D. Levin Center for Chemical Physics. National Bureau of Standards, Gaithersburg, MD 20899 The available data on gas phase basicities and proton affinities of molecules are compiled and evaluated. Tables giving the molecules ordered (1) according to proton affinity and (2) according to empirical formula, sorted alphabetically are provided. -
AASLD PRACTICE GUIDELINES Diagnosis and Management of Autoimmune Hepatitis
AASLD PRACTICE GUIDELINES Diagnosis and Management of Autoimmune Hepatitis Michael P. Manns,1 Albert J. Czaja,2 James D. Gorham,3 Edward L. Krawitt,4 Giorgina Mieli-Vergani,5 Diego Vergani,6 and John M. Vierling7 This guideline has been approved by the American ment on Guidelines;3 and (4) the experience of the Association for the Study of Liver Diseases (AASLD) authors in the specified topic. and represents the position of the Association. These recommendations, intended for use by physi- cians, suggest preferred approaches to the diagnostic, 1. Preamble therapeutic and preventive aspects of care. They are intended to be flexible, in contrast to standards of Clinical practice guidelines are defined as ‘‘systemati- care, which are inflexible policies to be followed in ev- cally developed statements to assist practitioner and ery case. Specific recommendations are based on rele- patient decisions about appropriate heath care for spe- vant published information. To more fully characterize 1 cific clinical circumstances.’’ These guidelines on the quality of evidence supporting the recommenda- autoimmune hepatitis provide a data-supported tions, the Practice Guidelines Committee of the approach to the diagnosis and management of this dis- AASLD requires a class (reflecting benefit versus risk) ease. They are based on the following: (1) formal and level (assessing strength or certainty) of evidence review and analysis of the recently-published world lit- to be assigned and reported with each recommenda- erature on the topic [Medline search]; (2) American tion.4 The grading system applied to the recommenda- College of Physicians Manual for Assessing Health tions has been adapted from the American College of 2 Practices and Designing Practice Guidelines; (3) Cardiology and the American Heart Association Prac- guideline policies, including the AASLD Policy on the tice Guidelines, and it is given below (Table 1). -
Nerve Agent - Lntellipedia Page 1 Of9 Doc ID : 6637155 (U) Nerve Agent
This document is made available through the declassification efforts and research of John Greenewald, Jr., creator of: The Black Vault The Black Vault is the largest online Freedom of Information Act (FOIA) document clearinghouse in the world. The research efforts here are responsible for the declassification of MILLIONS of pages released by the U.S. Government & Military. Discover the Truth at: http://www.theblackvault.com Nerve Agent - lntellipedia Page 1 of9 Doc ID : 6637155 (U) Nerve Agent UNCLASSIFIED From lntellipedia Nerve Agents (also known as nerve gases, though these chemicals are liquid at room temperature) are a class of phosphorus-containing organic chemicals (organophosphates) that disrupt the mechanism by which nerves transfer messages to organs. The disruption is caused by blocking acetylcholinesterase, an enzyme that normally relaxes the activity of acetylcholine, a neurotransmitter. ...--------- --- -·---- - --- -·-- --- --- Contents • 1 Overview • 2 Biological Effects • 2.1 Mechanism of Action • 2.2 Antidotes • 3 Classes • 3.1 G-Series • 3.2 V-Series • 3.3 Novichok Agents • 3.4 Insecticides • 4 History • 4.1 The Discovery ofNerve Agents • 4.2 The Nazi Mass Production ofTabun • 4.3 Nerve Agents in Nazi Germany • 4.4 The Secret Gets Out • 4.5 Since World War II • 4.6 Ocean Disposal of Chemical Weapons • 5 Popular Culture • 6 References and External Links --------------- ----·-- - Overview As chemical weapons, they are classified as weapons of mass destruction by the United Nations according to UN Resolution 687, and their production and stockpiling was outlawed by the Chemical Weapons Convention of 1993; the Chemical Weapons Convention officially took effect on April 291997. Poisoning by a nerve agent leads to contraction of pupils, profuse salivation, convulsions, involuntary urination and defecation, and eventual death by asphyxiation as control is lost over respiratory muscles. -
Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development
toxins Review Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development Christine Rasetti-Escargueil * and Michel R. Popoff Toxines Bacteriennes, Institut Pasteur, 75724 Paris, France; [email protected] * Correspondence: [email protected] Abstract: Botulinum neurotoxins (BoNTs) show increasing therapeutic applications ranging from treatment of locally paralyzed muscles to cosmetic benefits. At first, in the 1970s, BoNT was used for the treatment of strabismus, however, nowadays, BoNT has multiple medical applications including the treatment of muscle hyperactivity such as strabismus, dystonia, movement disorders, hemifacial spasm, essential tremor, tics, cervical dystonia, cerebral palsy, as well as secretory disorders (hyperhidrosis, sialorrhea) and pain syndromes such as chronic migraine. This review summarizes current knowledge related to engineering of botulinum toxins, with particular emphasis on their potential therapeutic applications for pain management and for retargeting to non-neuronal tissues. Advances in molecular biology have resulted in generating modified BoNTs with the potential to act in a variety of disorders, however, in addition to the modifications of well characterized toxinotypes, the diversity of the wild type BoNT toxinotypes or subtypes, provides the basis for innovative BoNT- based therapeutics and research tools. This expanding BoNT superfamily forms the foundation for new toxins candidates in a wider range of therapeutic options. Keywords: botulinum neurotoxin; Clostridium botulinum; therapeutic application; recombinant toxin; toxin engineering Key Contribution: Botulinum neurotoxins (BoNTs) are the deadliest toxins with an increasing number of medical applications. The generation of modified BoNTs has provided innovative tools Citation: Rasetti-Escargueil, C.; Popoff, for specific medical applications. M.R. Engineering Botulinum Neuro- toxins for Enhanced Therapeutic Ap- plications and Vaccine Development. -
A Toxicological Review of the Products of Combustion
HPA-CHaPD-004 A Toxicological Review of the Products of Combustion J C Wakefield ABSTRACT The Chemical Hazards and Poisons Division (CHaPD) is frequently required to advise on the health effects arising from incidents due to fires. The purpose of this review is to consider the toxicity of combustion products. Following smoke inhalation, toxicity may result either from thermal injury, or from the toxic effects of substances present. This review considers only the latter, and not thermal injury, and aims to identify generalisations which may be made regarding the toxicity of common products present in fire smoke, with respect to the combustion conditions (temperature, oxygen availability, etc.), focusing largely on the adverse health effects to humans following acute exposure to these chemicals in smoke. The prediction of toxic combustion products is a complex area and there is the potential for generation of a huge range of pyrolysis products depending on the nature of the fire and the conditions of burning. Although each fire will have individual characteristics and will ultimately need to be considered on a case by case basis there are commonalities, particularly with regard to the most important components relating to toxicity. © Health Protection Agency Approval: February 2010 Centre for Radiation, Chemical and Environmental Hazards Publication: February 2010 Chemical Hazards and Poisons Division £15.00 Chilton, Didcot, Oxfordshire OX11 0RQ ISBN 978-0-85951- 663-1 This report from HPA Chemical Hazards and Poisons Division reflects understanding and evaluation of the current scientific evidence as presented and referenced in this document. EXECUTIVE SUMMARY The Chemical Hazards and Poisons Division (CHaPD) is frequently required to advise on the health effects arising from incidents due to fires. -
Lllostridium Botulinum Neurotoxinl I H
MICROBIOLOGICAL REVIEWS, Sept. 1980, p. 419-448 Vol. 44, No. 3 0146-0749/80/03-0419/30$0!)V/0 Lllostridium botulinum Neurotoxinl I H. WJGIYAMA Food Research Institute and Department ofBacteriology, University of Wisconsin, Madison, Wisconsin 53706 INTRODUCTION ........ .. 419 PATHOGENIC FORMS OF BOTULISM ........................................ 420 Food Poisoning ............................................ 420 Wound Botulism ............................................ 420 Infant Botulism ............................................ 420 CULTURES AND TOXIN TYPES ............................................ 422 Culture-Toxin Relationships ............................................ 422 Culture Groups ............................................ 422 GENETICS OF TOXIN PRODUCTION ......................................... 423 ASSAY OF TOXIN ............................................ 423 In Vivo Quantitation ............................................ 424 Infant-Potent Toxin ............................................ 424 Serological Assays ............................................ 424 TOXIC COMPLEXES ............................................ 425 Complexes 425 Structure of Complexes ...................................................... 425 Antigenicity and Reconstitution .......................... 426 Significance of Complexes .......................... 426 Nomenclature ........................ 427 NEUROTOXIN ..... 427 Molecular Weight ................... 427 Specific Toxicity ................... 428 Small Toxin .................. -
Health Aspects of Biological and Chemical Weapons
[cover] WHO guidance SECOND EDITION WORLD HEALTH ORGANIZATION GENEVA DRAFT MAY 2003 [inside cover] PUBLIC HEALTH RESPONSE TO BIOLOGICAL AND CHEMICAL WEAPONS DRAFT MAY 2003 [Title page] WHO guidance SECOND EDITION Second edition of Health aspects of chemical and biological weapons: report of a WHO Group of Consultants, Geneva, World Health Organization, 1970 WORLD HEALTH ORGANIZATION GENEVA 2003 DRAFT MAY 2003 [Copyright, CIP data and ISBN/verso] WHO Library Cataloguing-in-Publication Data ISBN xxxxx First edition, 1970 Second edition, 2003 © World Health Organization 1970, 2003 All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: [email protected]).